Sarcoma Clinical Trial Landscape

The sarcoma clinical trial landscape in 2026

Sarcoma encompasses more than 70 distinct histologic subtypes arising from mesenchymal tissues, bone, muscle, fat, cartilage, and connective tissue, making it among the most molecularly heterogeneous disease categories in oncology. Collectively, sarcomas represent approximately 1% of adult cancers but are disproportionately represented in pediatric and young adult populations and carry substantial mortality in advanced and metastatic settings. The field has historically suffered from small patient populations, insufficient randomized data, and a limited approved drug armamentarium dominated by doxorubicin, ifosfamide, and gemcitabine/docetaxel regimens developed decades ago. That is now changing.

The transformation of GIST (gastrointestinal stromal tumor) through KIT/PDGFRA-targeted therapy has become the paradigm case for sarcoma drug development, and a proof-of-concept for the broader field that molecular driver identification leads to dramatically better outcomes. Imatinib (Gleevec, Novartis) turned a near-uniformly fatal disease into a manageable chronic condition; subsequent lines of therapy now include sunitinib, regorafenib, ripretinib (Qinlock, Deciphera), and avapritinib (Ayvakit, Blueprint Medicines), which specifically targets PDGFRA D842V-mutant GIST, historically imatinib-resistant. The molecular testing infrastructure built for GIST is now being applied across sarcoma broadly, with NTRK, ALK, RET, and SS18-SSX fusions enabling targeted therapy in synovial sarcoma and other translocation-driven subtypes.

The recruiting trials in our database span GIST, soft tissue sarcoma (STS) including leiomyosarcoma, liposarcoma, and synovial sarcoma, bone sarcomas (osteosarcoma, Ewing sarcoma), and ultra-rare subtypes including alveolar soft part sarcoma (ASPS) and clear cell sarcoma. Active sponsors include the NCI through SARC (Sarcoma Alliance for Research through Collaboration), Memorial Sloan Kettering, Ratio Therapeutics, and AbbVie. The pipeline reflects both histology-agnostic basket approaches and histology-specific molecular designs.

• GIST. KIT exon 11/9/13/14 mutations (imatinib/sunitinib/regorafenib), KIT exon 17/18 and PDGFRA D842V (avapritinib), SDH-deficient GIST, NF1-associated GIST, pan-KIT inhibition (ripretinib)
• Soft tissue sarcoma, leiomyosarcoma (gemcitabine/docetaxel, trabectedin, eribulin in liposarcoma), synovial sarcoma (SS18-SSX fusion, NY-ESO-1 T-cell therapies), undifferentiated pleomorphic sarcoma
• Liposarcoma. CDK4/6 amplification in well-differentiated/dedifferentiated LPS (palbociclib/abemaciclib), MDM2 amplification (MDM2 inhibitors milademetan, navtemadlin), WD/DDLPS distinctions
• Bone sarcoma, osteosarcoma (MAP chemotherapy, mifamurtide, checkpoint inhibitors), Ewing sarcoma/EWSR1-FLI1 fusion (VIDE/VDC-IE chemotherapy, EWS-FLI1 inhibitor TK216)
• Translocation-driven rare subtypes, alveolar soft part sarcoma (ASPSCR1-TFE3, MET pathway, cabozantinib), clear cell sarcoma, epithelioid sarcoma (INI1-loss, tazemetostat)
• Immunotherapy combinations, pembrolizumab in STS (SARC028, KEYNOTE studies), nivolumab combinations, TIL therapy for synovial sarcoma
• Novel mechanisms, trabectedin (Yondelis, marine-derived, approved in liposarcoma/LMS), eribulin in liposarcoma (approved), VEGFR/multi-kinase inhibitors (pazopanib approved in STS)

What we monitor for sarcoma

Our system pulls from the ClinicalTrials.gov API every day. For a sarcoma watch profile, you can configure a saved search for:

• Keywords: "sarcoma," "soft tissue sarcoma," "GIST," "gastrointestinal stromal tumor," "leiomyosarcoma," "liposarcoma," "osteosarcoma," "Ewing sarcoma," "synovial sarcoma," "avapritinib," "ripretinib," "trabectedin," "eribulin," "CDK4," "MDM2," "EWSR1," "SS18-SSX," "tazemetostat"
• Phase filters: Phase 1 (novel mechanisms, rare subtype basket trials, first-in-human), Phase 2 (histology-specific, molecular biomarker-selected), Phase 3 (registration, randomized controlled in STS/GIST)
• Sponsor type: NCI/SARC cooperative group, academic sarcoma centers (MSK, MD Anderson, Royal Marsden), biotech (Blueprint Medicines, Deciphera, Epizyme/Ipsen), large pharma (AbbVie, Pfizer)
• Study status: not yet recruiting, recruiting, active not recruiting
• Sub-type: GIST by exon mutation, LPS subtype (WD/DD/PL/RC), bone vs. soft tissue, pediatric/adolescent (Ewing, osteosarcoma), adult rare subtypes (ASPS, EHE, CCS)

GIST as the sarcoma success story: and what it means for histology-specific development

The GIST story begins with a chance observation: Peter Reichardt and colleagues in 2001 reported a dramatic response to imatinib in a single patient with metastatic GIST, a disease for which median survival had been less than 18 months. The subsequent B2222 phase 2 trial showed response rates above 50% with durable remissions in a disease previously refractory to all systemic therapy. The key molecular insight was that GIST arises from oncogenic mutations in KIT (approximately 75–80% of cases) or PDGFRA (approximately 10%), both receptor tyrosine kinases directly inhibited by imatinib. For the first time, a sarcoma had a tractable molecular target and a matched approved therapy.

The decades since have produced a complete treatment algorithm stratified by mutation: KIT exon 11 mutations respond best to imatinib first-line; KIT exon 9 mutations require higher imatinib doses or sunitinib; acquired resistance mutations in KIT exons 17 and 18 are the primary mechanism of imatinib progression and are addressed by ripretinib (a switch-control KIT/PDGFRA inhibitor) and avapritinib (the first selective PDGFRA D842V inhibitor). SDH-deficient GIST, lacking succinate dehydrogenase, driver-negative by conventional testing, represents a biologically distinct entity with different behavior and treatment principles. NF1-associated GIST is yet another distinct molecular class. The lesson: molecular subtype determination is not optional in GIST; it is the foundation of every treatment and clinical trial decision.

The sarcoma field is now attempting to replicate this success across other subtypes. NTRK fusions, present in infantile fibrosarcoma and a small subset of adult STS, are targetable with larotrectinib and entrectinib (both approved agnostic to tumor type). ALK rearrangements in inflammatory myofibroblastic tumor respond to alectinib and crizotinib. RET fusions appear in a subset of STS and are targetable with selpercatinib. The emergence of basket trial designs, enrolling patients based on molecular alteration rather than histology, has made genomic profiling mandatory for sarcoma patients entering clinical trials, and has created an entirely new class of clinical registrations that BD and research teams must track: a "sarcoma NTRK basket" trial is as relevant to a sarcoma-focused team as a histology-specific protocol.

Who uses sarcoma trial monitoring

• Oncology pharma and biotech BD teams: sarcoma is a highly molecular disease; BD teams track KIT/PDGFRA, CDK4/MDM2, NTRK/ALK/RET fusion, and EZH2 programs as potential licensing and acquisition targets at Phase 1/2
• Sarcoma-focused CROs: identifying new sponsor relationships and site opportunities, particularly for rare subtype-specific and basket trials requiring specialized molecular testing infrastructure
• Sarcoma patient advocacy organizations: tracking access to Phase 1/2 trials for patients with rare subtypes who have exhausted standard options; monitoring compassionate use and expanded access programs
• Academic sarcoma programs and multidisciplinary tumor boards: monitoring industry programs for investigator-site participation, biomarker collaboration, and patient referral pathways to novel trials
• Oncology investors: sarcoma basket trials and molecular programs often signal earlier-stage platform value; monitoring Phase 1/2 registrations for pipeline intelligence